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Urotensin II (UTN) is a vasoactive substance that may induce
vasoconstriction or vasodilatation. Although this peptide is
seen as a vasculotoxic substance, to date there is no
prospective study examining the relationship between UTN
and hard end points like cardiovascular (CV) events. UTN is
much increased in end-stage renal disease (ESRD) and this
disease may represent a useful natural model to explore the
relationship between UTN and CV outcomes. In this study, we
analysed the relationship between plasma UTN and incident
CV events (fatal and non-fatal) in a cohort of 191
haemodialysis patients followed up for an average time of 3.6
years (range 0.07–5.8 years). Plasma UTN in haemodialysis
patients (median: 6.5 ng/ml) was twice higher than in healthy
subjects (median: 3.3 ng/ml). During the follow-up period, 94
patients died and 88 had incident fatal and non-fatal CV
events. UTN was significantly lower in patients with incident
CV events (median: 5.3 ng/ml) than in events-free patients
(median: 7.1 ng/ml), and in a Kaplan–Meier analysis, high UTN
was strongly and inversely associated with incident CV
events (Po0.001). Multivariate Cox’s regression analysis fully
confirmed plasma UTN as an inverse predictor of adverse CV
outcomes, and in this analysis, UTN resulted to be the third
factor in rank, after age and diabetes, explaining the
incidence of CV events. UTN is an inverse predictor of CV
outcomes in ESRD. Our data suggest that UTN should not be
necessarily seen as a vasculotoxic peptide in haemodialysis
patients.
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Urotensin II (UTN) is a cyclic undecapeptide with structural
homology to somatostatin, which binds to an orphan
G-protein receptor (GPR14) in the mouse and in humans.1–3
Initially found to have potent vasoconstrictive activities in
a variety of vessels from diverse species,4 it is now clear that
UTN also possesses endothelium-dependent vasodilatation
properties in the rat5,6 and in humans.7 The plasma concen-
tration of this peptide is increased in a variety of human
diseases such as essential hypertension,8 heart failure,9–14
liver cirrhosis,15 diabetic nephropathy16,17 and chronic renal
insufficiency.18 The observation that UTN is overexpressed in
coronary plaques in humans is of particular interest because
it suggests that this peptide may be implicated in athero-
matous complications in patients with coronary heart
disease.2 UTN in heart failure increases in parallel with
hormones fundamental for cardiovascular (CV) homeostasis
such as brain natriuretic peptide (BNP),14 a phenomenon
suggesting that high UTN participates in the counter-
regulatory response to systolic failure. The potential relevance
of UTN in CV biology is also highlighted by its high
concentration in atherosclerotic lesions.19
Notwithstanding the growing interest on this peptide, to
date there is no study in humans testing the relationship
between UTN and solid outcome measures like mortality and
incident CV events. This information is of obvious im-
portance for the interpretation of the biological relevance
of UTN because it was emphasized that there are arguments
for viewing this substance both as a vasculotoxic and as
a vasculoprotective one.4,20
End-stage renal disease (ESRD) is a condition where
circulating UTN is much increased and it was speculated
that UTN is implicated in CV complications in uraemic
individuals.18 Therefore, this disease may represent an useful
natural model to explore the relationship between UTN and
CV outcomes. Somewhat unexpectedly, in a pilot study in a
group of 63 well-nourished, uncomplicated, ESRD patients,
we found that UTN was inversely related to inflammation
markers and pulse pressure (Mallamaci F et al. XLI Congress
ERA-EDTA, 2004 (abstract); abstract book: 84pp). Likewise,
in a recent survey in a large cohort of dialysis patients, we
found that UTN was inversely, rather than directly, related
with CV stress hormones like norepinephrine (NE) and
BNP.21 These apparently paradoxical associations may
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suggest that relatively higher plasma UTN levels may signal a
vasculoprotective situation in these patients.
To shed further light on this issue herein, we analyse the
relationship between UTN and incident CV events in this
cohort over a follow-up extended to 5.8 years.
RESULTS
The prevalence of diabetes mellitus in the study cohort was
15% (i.e. 28 patients out of 191). Ninety-four patients had
had one or more CV events (electrocardiogram documented
angina or myocardial infarction, peripheral artery diseases,
arrhythmia, transient ischaemic attacks and stroke). Plasma
UTN in haemodialysis patients (median: 6.5 ng/ml, inter-
quartile range 2.9–11.5 ng/ml) was twice higher than in
healthy subjects (median: 3.3, 2.4–4.6 ng/ml) (Figure 1); it
exceeded the upper limit of the normal range (90th percentile
in healthy subjects: 6.8 ng/ml) in 92 out of 191 cases (48%)
and it was higher than the median value in healthy subjects
(3.3 ng/ml) in 136 cases (71%).
In Table 1, patients are grouped according to whether or
not they developed incident CV events during the 5.8 years
follow-up. Patients with incident CV events were older, with a
higher prevalence of smokers and diabetics, with a higher
burden of background CV complications and more likely
to be on antihypertensive treatment. Furthermore, serum
C-reactive protein (CRP) and plasma total homocysteine
concentrations in these patients tended to be higher than
in those who did not develop such events. NE and BNP were
both raised in patients with incident CV events, but only BNP
significantly so.
In this analysis, plasma UTN was significantly lower in
patients with incident CV events (median: 5.3, 2.4–11.0 ng/
ml) than in events-free patients (median: 7.1, 3.8–11.8 ng/ml)
(Table 1) and inversely related both with plasma NE
(r¼0.28, Po0.001) and BNP (r¼0.41, Po0.001).
Plasma urotensin and incident CV events
During the follow-up period, 94 patients died and 88 had
incident CV events (fatal in 63 patients and non-fatal in the
remaining 25 patients). Plasma UTN was lower in patients
who died (median: 5.6, 2.4–11.5 ng/ml) than in those who
survived (median: 6.8, 3.6–11.3 ng/ml), but the difference was
not significant (P¼ 0.20). Likewise, plasma UTN expressed as
a dichotomous variable (on the basis of the median value in
healthy subjects: cutoff 3.3 ng/ml) was weakly related to death
at univariate Cox’s analysis (P¼ 0.05), but this association
become weaker on multivariate analysis (P¼ 0.09). How-
ever, in a Kaplan–Meier analysis, high UTN was strongly
(Po0.001) and inversely associated with incident CV events
(Figure 2). Multivariate Cox’s regression analysis fully
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Figure 1 | Plasma levels of UTN in healthy subjects and in
haemodialysis patients.
Table 1 | Main demographic, somatometric, clinical and biochemical data of patients
Without CV events (n=103) With CV events (n=88) P-value
Age (years) 54716 64711 o0.001
Duration of maintenance hemodialysis (months) 41 (18–110) 46 (22–103) 0.25
Male sex, n (%) 56 (54) 50 (57) 0.73
Smokers, n (%) 32 (31) 42 (48) 0.02
Diabetics, n (%) 7 (7) 21 (24) 0.001
With background CV complications, n (%) 36 (35) 58 (66) o0.001
On antihypertensive therapy, n (%) 30 (29) 42 (48) 0.008
Haemoglobin (g/l) 108717 106720 0.34
Albumin (g/l) 4275 4175 0.14
Cholesterol (mg/dl) 207757 207755 0.99
Calcium phosphate (mmol2/l2) 4.671.3 4.571.0 0.71
Systolic pressure (mmHg) 138722 144727 0.15
Diastolic pressure (mmHg) 78711 75715 0.10
Heart rate (beats/min) 78710 79711 0.55
Urotensin (ng/ml) 7.1 (3.8–11.8) 5.3 (2.4–11.0) 0.04
CRP (mg/l) 4.7 (3.4–15.3) 9.6 (3.5–18.3) 0.06
Homocysteine (mmol/l) 25.7 (18.2–38.5) 28.7 (21.9–47.1) 0.08
NE (nmol/l) 2.78 (1.74–4.38) 3.31(1.64–6.33) 0.40
Brain natriuretic peptide (pmol/l) 15.9 (4.9–29.2) 28.9(13.9–48.9) o0.001
Data are expressed mean7s.d., median and inter-quartile range or as percent frequency, as appropriate.
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confirmed plasma UTN as an inverse predictor of adverse CV
outcomes (Table 2), and in this analysis, UTN resulted to be
the third factor in rank, after age and diabetes, explaining the
incidence of CV events (Table 2). Of note, the inverse
association between UTN and CV events was also confirmed
in a statistical model adjusting for plasma NE and BNP
(hazard ratio (1 Ln unit increase in UTN): 0.70, 95%
confidence interval: 0.50–0.97). The probability of incident
CV events (adjusted for other risk factors) in relationship to
plasma UTN is further analysed in Figure 3. This analysis
shows that the risk of CV complications is low in patients
with relatively higher UTN levels, but that it is very high in
patients at the bottom end of UTN levels.
DISCUSSION
This study confirms that UTN is frequently increased in
ESRD patients and for the first time shows that this peptide is
an independent, inverse predictor of CV morbid events in
patients with ESRD.
UTN is a multifaceted peptide expressed in the central
nervous system and in a wide array of peripheral tissues
including myocardial cells, the endothelium and vascular
smooth muscle cells.1 The effects of UTN on vascular tone
depend on vascular bed, species and dose.1 In humans, both
intense vasoconstrictive22 and vasodilatory23 responses or no
response24 have been described. In isolated human pulmo-
nary and abdominal resistance arteries, UTN appears to be
a strong vasodilator, equipotent to adrenomedullin.7 UTN
is intensely represented in inflamed atherosclerotic lesions
in patients with coronary heart disease.19 Although on first
consideration this effect suggests that UTN could be a
noxious agent for the vascular system, the interpretation of
this finding remains unclear because UTN may both
amplify25 or decrease the effect of inflammation.26
So far, plasma UTN has been measured only in two studies
in patients with chronic renal insufficiency. In the first study,
UTN was twofold higher in patients with moderate to severe
renal insufficiency and threefold higher in patients with
ESRD in comparison to healthy subjects.18 Likewise, in the
second study in diabetic patients, UTN was about 1.8 times
higher in patients with severe chronic renal insufficiency as
compared to those with moderate and mild renal insuffi-
ciency.16 Increased renal synthesis rather than reduced renal
excretion seems to be the cause of high plasma UTN in
chronic renal insufficiency.27 The pathophysiological and
clinical implications of this alteration are still unknown
mostly because, given the autocrine–paracrine mechanism of
action of this peptide, circulating levels may not reflect the
effects of this peptide at organ and tissue level.
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Figure 2 | Kaplan-Meier survival analysis of fatal and non-fatal CV
events. Dialysis patients were divided into two groups on the basis
of the median value of plasma UTN in healthy subjects.
Table 2 | Cox regression analysis of fatal and non-fatal
cardiovascular events
Units of increase
Hazard ratio
(95% CI) P-value
Age 1 year 1.05 (1.03–1.08) o0.001
Diabetes 0=no; 1=yes 2.73 (1.55–4.82) o0.001
Urotensin Ln (values in ng/ml) 0.60 (0.45–0.81) o0.001
Homocysteine Ln (values in mmol/l) 1.83 (1.23–2.72) 0.003
Smoking 0=no; 1=yes 1.76 (1.13–2.74) 0.01
Antihypertensive
therapy
0=no; 1=yes 1.75 (1.10–2.79) 0.02
Previous CV events 0=no; 1=yes 1.48 (0.92–2.37) 0.10
CRP 10 mg/l 0.96 (0.86–1.07) 0.50
Data are expressed as hazard ratio and 95% confidence and P-value.
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Figure 3 | Relationship between probability of fatal and non-fatal
CV events in relationship to plasma UTN during the 5.8 years
follow-up. The point estimates (and 95% confidence interval (CI))
were calculated by using the equation derived from the multiple Cox
regression analysis reported in Table 2. In this equation, all terms, but
UTN, were set to the corresponding average value.
Kidney International (2006) 69, 1253–1258 1255
C Zoccali et al.: Urotensin II in end-stage renal disease o r i g i n a l a r t i c l e
UTN, survival and CV outcomes
Plasma UTN concentration varies by one order of magnitude
or more according to methods of measurement and radio-
receptor assays give consistently higher values than radio-
immunoassay.28 In the present study, we employed a fairly
reliable enzyme-linked immunosorbent assay and performed
additional studies to exclude cross-reactivity of the antibody
with pre–pro UTN and urotensin-like peptide (see Materials
and methods), and UTN in our study population was of
the same order of magnitude reported in three recent
studies employing a similar enzyme-linked immunosorbent
assay.15,29,30 As previously alluded, the prognostic implication
of high plasma levels of UTN in human diseases has not been
explored. The question is relevant mostly because this
peptide may be seen both as a vasculoprotective and as a
vasculotoxic agent and because in previous surveys we found
that in ureamic individuals UTN signals a vasculoprotective
situation.4,20
ESRD represents a prototypical chronic inflammatory
state conveying a very high risk for CV complications.31 The
mortality rate of our cohort was 13%/year, that is, very close
to that reported in the European Registry of dialysis and
transplantation and about 60% patients died of CV causes,
which further again highlights the high risk of uraemic
syndrome. UTN increases in patients with decompensated
heart failure30 and during cardiac ischaemia.29 However,
these diseases did not confound data interpretation in the
present study because by protocol, we excluded patients with
evidence of heart failure or inter-current anginal episodes at
baseline. In the present study, by multiple forms of analysis
adjusting for traditional and emerging risk factors, including
plasma NE and BNP, UTN emerged as an inverse rather than
as a direct predictor of incident CV events. UTN is expressed
to an important degree in human endothelial cells,32 and
human UTN is a potent endothelium-dependent vasodilator
in human pulmonary and abdominal resistance arteries7 and
in resistance vessels in the rat where it acts through the release
of nitric oxide as well as of endothelium hyperpolarizing
factor.33 Endothelial function is notoriously compromised in
ESRD.34 It can be hypothesized that the inverse link between
UTN and CV outcomes be the expression of an UTN-driven
counter-regulatory response aimed at restoring endothelial
function.35 However, an alternative hypothesis deserving
careful consideration is that the inverse association between
UTN and incident CV events represents an additional
example of the paradoxical relationships between risk factors
and clinical outcomes in this population.36 It was suggested
that one way for circumventing the difficulties posed by
‘reverse epidemiology’ in ESRD is exploring the link between
risk factors and outcomes in patients without malnutrition
and major CV complications.37 In line with the present study,
in a pilot study restricted to 60 well-nourished, uncompli-
cated ESRD patients not assuming antihypertensive drugs, we
observed inverse links between UTN and a series of surrogate
outcome measures including inflammation markers, pulse
pressure and sympathetic neuromediators (Mallamaci F et al.
XLI Congress ERA-EDTA, 2004 (abstract); abstract book:
84pp). Furthermore, again fully in line with the present
study, in a survey in this same cohort, we found inverse links
between UTN and CV stress hormones (NE and BNP).21
These coherent results make unlikely that these apparently
paradoxical relationships be the expression of the inverse
epidemiology of ESRD, but the issue clearly deserves further
investigations and external validation in other cohorts.
Our study has limitations. We cannot establish causality
and the hypothesis we have advanced to interpret the link
between urotensin and incident CV events remains specu-
lative. Further studies are warranted to explore the role of
this most interesting peptide in ureamic patients.
UTN antagonists are being developed and these substances
will soon provide new stimulating opportunities for studying
the role of UTN in the complex pathophysiological adapta-
tions of the uraemic syndrome.
MATERIALS AND METHODS
Protocol
The protocol was in conformity to the ethical guidelines of
our institution and informed consent was obtained from each
participant. To minimize the effect of cyclic variations of body
fluid volume status on CV control systems, all measurements were
performed during a mid-week non-dialysis day, always between
0800 and 1300 hours.
Patients and controls
One hundred and ninety-one haemodialysis patients (106 men and
85 women) who had been on maintenance haemodialysis for at least
6 months (median duration of haemodialysis: 43 months, inter-
quartile range: 20–105 months) without clinical evidence of heart
failure and ejection fraction 435% and without inter-current
cardiac ischaemia or other illnesses were considered eligible for the
study. The main demographic and clinical characteristics of the
patients included in the study are detailed in Table 1. All patients
had 24 h urine volume p200 ml/day and were being treated thrice
weekly with standard bicarbonate dialysis (Na 138 mmol/l, HCO3
35 mmol/l, K 1.5 mmol/l, Ca 1.25 mmol/l, Mg 0.75 mmol/l) by
cuprophan or semisynthetic membranes (dialysis filters surface
area: 1.1–1.7 m2). The average fractional urea clearance (Kt/V) in
these patients was 1.2170.27. Seventy-four patients were habitual
smokers (22716 cigarettes/day). One hundred and three patients
were on treatment with erythropoietin. Seventy-two patients were
being treated with antihypertensive drugs.
The control group was formed by 167 consecutive normotensive
healthy blood donors well matched to dialysis patients for age
(average age: 58 years; 131 men and 36 women).
Follow-up
After the initial assessment, patients were followed up for an average
time of 3.6 years (range 0.07–5.8 years). During the follow-up CV
events (electrocardiogram documented anginal episodes and
myocardial infarction, electrocardiogram documented arrhythmia,
heart failure, transient ischaemic attacks and stroke and other
thrombotic events, except arteriovenous thrombosis) and death were
accurately recorded. Each death was reviewed and assigned an
underlying cause by a panel of five physicians. As a part of the
review process, all available medical information about each death
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was collected. This information always included study and hospitali-
zation records. In the case of an out-of-hospital death family
members were interviewed by telephone to better ascertain the
circumstances surrounding death.
Laboratory measurements
Blood sampling was performed, after an overnight fast, between
0800 and 1000 hours always during a non-dialysis day. After
20–30 min of quiet resting in semirecumbent position, samples were
taken into chilled ethylenediaminetetraacetic acid vacutainers,
placed immediately on ice, centrifuged within 30 min at 41C and
the plasma stored at 801C until assay. Serum cholesterol, albumin,
calcium and phosphate measurements were made using standard
methods in the routine clinical laboratory. Plasma UTN was
determined by a high-sensitivity enzyme immunoassay employing
an antibody (Phoenix Pharmaceuticals, Belmont, CA, USA), which
does not cross-react with endothelin-1, angiotensin II, adreno-
medullin, calcitonin-gene-related peptide and BNP. Furthermore,
investigations specifically related to the present study were
performed at Phoenix Laboratories to test the cross-reactivity of
this antibody with human pre–pro UTN (10–125) and UTN-related
peptide. These additional studies showed no cross-reactivity (0%)
with pre–pro UTN and 19.8% cross-reactivity with UTN-related
peptide. The intra- and inter-assay coefficients of variation of this
assay were 12 and 13%, respectively.
The methods of measurement of plasma NE,38 serum CRP, BNP
and plasma total homocysteine were reported elsewhere.39
Statistical analysis
Data are reported as mean7s.d., median and inter-quartile range or
as percent frequency and comparisons between groups were made
by t-test, Mann–Whitney test or w2 test, as appropriate. Relation-
ships between paired parameters were analysed by Pearson’s product
moment correlation coefficient. Data that did not show a Gaussian
distribution were log transformed. Missing values (albumin, n¼ 1;
cholesterol, n¼ 1; calcium phosphate, n¼ 1; CRP, n¼ 1; BNP¼ 2)
were set at the average value of the corresponding variable.
The independent association between plasma UTN with death
and incident CV events (fatal and non-fatal) was analysed by
multiple Cox regression analysis. We firstly identified variables that
differed (with Po0.10) in patients with and without incident CV
events. Tested covariates included plasma UTN as well as age,
duration of maintenance haemodialysis, sex, diabetes, smoking,
antihypertensive therapy, previous CV events, haemoglobin, albu-
min, cholesterol, calcium phosphate product, arterial pressure and
heart rate, CRP and homocysteine. UTN and variables that differed
between groups were then included into a multivariate Cox model.
Furthermore, to ensure adequate statistical power (i.e. at least 10
events per covariate), the prediction power of UTN adjusted for NE
and BNP for incident CV events was tested in a separate statistical
model, which was identical to the previous one but including NE
and BNP instead of CRP and homocysteine. The proportional-
hazards assumption of Cox models was preliminarily verified by
Shoenfeld’s method.40 Furthermore, to assess the functional form of
covariates included into the Cox model, we analysed the Martingale
residuals.41 On the basis of this preliminary analysis, plasma UTN,
total homocysteine, BNP and NE were introduced into the Cox
regression in logarithmic form (ln). Data are expressed as hazard
ratio and 95% confidence interval. Point estimates of the probability
of fatal and non-fatal CV events associated to plasma levels of UTN
were calculated by using the equation derived from the multiple Cox
regression analysis reported in Table 2. In this equation, all terms,
but UTN, were set to the corresponding average value. Confidence
intervals of estimated probabilities were calculated by the standard
formula.42 All calculations were made using a standard statistical
package (SPSS for Windows Version 9.0.1, Chicago, IL, USA,
11 March, 1999).
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